The United States Patent and Trademark Office (USPTO) has published a new patent application, US20260085046A1, filed on August 7, 2025. The application details compounds of Formula (I) and pharmaceutically acceptable salts thereof, designed for dual function: NADPH oxidase inhibition and histone deacetylase inhibition. It also describes a method for treating cancer using these compounds and a pharmaceutical composition containing them.

This publication represents a new patent application and does not impose immediate regulatory obligations. However, it signifies potential future intellectual property rights for the inventors and their associated entities. Companies involved in oncology drug development, particularly those researching NADPH oxidase or histone deacetylase inhibitors, should monitor the progress of this application and similar filings for competitive intelligence and potential licensing opportunities.